TSI Launches New Vegetarian Glucosamine Ingredient Line
TSI Group Ltd. says its new GlucosaGreenDF avoids the supply challenges of glucosamine sourced from shellfish-derived chitin, in addition to providing vegetarian-friendly options.
Photo © iStockphoto.com/Raycat
Glucosamine, one of the most popular joint-health ingredients, has historically been produced from shellfish-derived chitin-a starting material that presents several supply challenges and is out of reach for vegan consumers. With that in mind, TSI Group (TSI; Missoula, MT) has announced the launch of GlucosaGreen DF, a line of vegan glucosamine ingredients it calls “the world’s first non-shellfish glucosamine branded product line produced by an innovative and patent-pending direct-fermentation technology with regulatory approval.”
A few reasons why shellfish-derived glucosamine can be difficult to work with are its unreliable supply issues, inconsistent quality, and potentially harmful impact on the environment where the shellfish are collected, depending on manufacturing conditions, TSI explains. GlucosaGreenDF, on the other hand, hopes to sidestep those issues, while also making glucosamine ingredients available to vegetarian and vegan consumers.
“The patent-pending, direct-fermentation manufacturing technology that supports GlucosaGreenDF is considered disruptive since it effectively addresses and offers efficient solutions to all of the challenges inherent in shellfish-derived chitin production processes,” says Joe Zhou, CEO of TSI, in the launch announcement. “The GlucosaGreenDF process is a totally transparent, fully traceable, cost-effective, and environmentally friendly solution for brands and ultimately the consumer.”
The new GlucosaGreenDF line currently includes several glucosamine ingredients, such as glucosamine hydrochloride, n-acetyl glucosamine, and glucosamine sulfates. TSI explains that all grades of the GlucosaGreenDF ingredients are tested for compliance with international monographs such as those established by the U.S. Pharmacopeial Convention (USP) and the European Pharmacopeia. They are also “manufactured under the highest-quality CGMP conditions,” TSI adds.
Read more:
Alternative Joint-Health Ingredients Are on the Rise
New Joint-Health Chewable Offers Alternative to Glucosamine and Chondroitin
UC-II Collagen More Effective for Knee Osteoarthritis Symptoms than Glucosamine and Chondroitin?
Michael Crane
Associate Editor
Nutritional Outlook Magazine
michael.crane@ubm.com
Kratom sees impressive sales growth despite its regulatory status and stigma
March 12th 2025Despite its controversy, kratom is a top-selling ingredient that consumers see value in. That said, brands need to work hard to demonstrate safety and quality of kratom products in the absence of legal regulatory status. Will kratom be able to overcome its stigma for even more growth and consumer acceptance?
DOJ asks Utah court to dismiss FTC lawsuit against Xlear Inc.
March 11th 2025On March 10, the DOJ and the defendant filed a stipulation to dismiss with prejudice the lawsuit in which each party agrees “to be responsible for its own costs and fees and agrees that no party shall be responsible to any other party for any fines, costs, fees, or penalties arising from this case.”
HHS announces efforts to eliminate independent conclusion of GRAS
Published: March 11th 2025 | Updated: March 11th 2025U.S. Department of Health and Human Services (HHS) Secretary, Robert F. Kennedy Jr., is directing the acting U.S. Food and Drug Administration’s (FDA) acting commissioner to explore rulemaking that would eliminate the independent conclusion of GRAS provision.
